Since the discovery of the gain-of-function mutation JAK2 V617F in 2005, an increasing number of mutations have been described in myeloproliferative neoplasms (MPN) and related myeloid malignancies. [1] [2] [3] [4] For instance, use of array-based techniques such as comparative genomic hybridization and single-nucleotide polymorphism (SNP) analysis led to the identification of genes involved in epigenetic regulation such as tet-oncogene family member 2 (TET2), additional sex combs like 1 (ASXL1) and enhancer of zeste 2 (EZH2). [5] [6] [7] Inactivating mutations in TET2, ASXL1 and EZH2 are considered to promote myeloid tumorigenesis because of epigenetic modulation of target genes. More recently, a whole-genome sequencing study in acute myeloid leukemia (AML) uncovered recurrent mutations in 22% of AML patients in another epigenetic regulator, the DNA methyltransferase 3A gene DNMT3A. 8 In this study, DNMT3A mutations were associated with poor outcome and, thus, are of clinical relevance. However, exact mechanisms of action of DNMT3A mutations are still unclear because global methylation patterns and 5-methylcytosine content in AML genomes were not significantly altered. Nevertheless, mutations of TET2, ASXL1, EZH2 and DNMT3A occur in a significant number of patients with myeloid malignancies underlining the pathogenic relevance of epigenetic changes.
On the basis of these findings we sought to explore the mutation frequency of DNMT3A in a series of well-characterized 'classic' MPN cases. In our study, 115 chronic-(n ¼ 80) or blast-phase (n ¼ 35) MPN cases were screened for DNMT3A mutations using direct DNA sequencing of all coding exons (2-23): essential thrombocythemia (ET), n ¼ 30; polycythemia vera (PV), n ¼ 30; primary myelofibrosis, n ¼ 16; post-ET MF, n ¼ 2; post-PV MF, n ¼ 2; AML secondary to MPN (sAML), n ¼ 35. In chronic-phase MPN, DNA from peripheral blood granulocytes was analyzed, whereas mononuclear cell DNA from bone marrow (n ¼ 9) or peripheral blood (n ¼ 26) was used in sAML cases. Mutation data on JAK2 V617F, MPL W515L, TET2 (exon 3-11), IDH1/2 (exons 4), ASXL1 (exon 12), CBL (exon 8-9) and EZH2 (exon 2-20) were available in all cases. Technical details on mutation assays are available on request. In addition, all cases were analyzed on Affymetrix (Santa Clara, CA, USA) 250K SNP arrays allowing for genome-wide screening of copy number alterations and uniparental disomies at high resolution. All patients gave written informed consent for molecular analyses. The study was approved by the Ethics Committee of the University Hospital of Ulm.
In total, 12 DNMT3A sequence variants were identified in our study, resulting in an overall frequency of 10% (12/115). Sequence variants were most frequently detected in sAML (17%, 6/35) and MF (15%, 3/20), followed by PV (7%, 2/30) and ET (3%, 1/30); of note, MF was secondary to ET or PV in 2/3 cases. All sequence variants were heterozygous, and none of the patients harbored more than one DNMT3A alteration. DNMT3A alterations consisted of eight nucleotide substitutions and four frameshift deletions; two nucleotide substitutions resulted in direct stop codons (E523 n and E477 n ), two represented missense alterations (N501S and W860R) and four affected the amino acid residue R882 recurrently (R882H, n ¼ 3; R882C n ¼ 1).
The alterations E477
n (n ¼ 1) and R882H/C (n ¼ 4) were already described by Ley et al. 8 as somatic nonsense and missense mutations, respectively. In our study, somatic origin could be proven in five cases, including two known (E477 n and R882H) and three novel (W305fs, R488fs and E523 n ) variants in which buccal swap or T-cell DNA were available ( Table 1) . As the presence of frameshift deletions (P264fs and D768fs) in germline is unlikely, tumor-specific origin remains uncertain in the two missense alterations, N501S and W860R in ET and sAML, respectively. Although alignment to distinct SNP databases (http://www.ncbi.nlm.nih.gov/sites/snp; http://genome.ucsc.edu/ cgi-bin/hgGateway; http://www.ensembl.org/Homo_sapiens/Info/ Index) did not identify one of these sequence variants as a polymorphism, they were excluded from the analysis. Consequently, the overall mutation frequency of DNMT3A decreased to 9% (10/115); ET, 0% (0/30); PV, 7% (2/30); sAML, 14% (5/35); and MF 15% (3/20) ( Figure 1 ). Interestingly, the majority of mutations (60%, 6/10) were located in two important protein domains, namely the proline-tryptophan-tryptophan-proline motif (n ¼ 1) and the methyltransferase domain (n ¼ 5).
We next analyzed patterns of cooperativity among the different mutations. None of the DNMT3A-altered cases harbored MPL, CBL, TET2 or EZH2 mutations; however, DNMT3A alterations occurred concurrently with JAK2, IDH1/2 and ASXL1 gene mutations (Table 2) ; 70% (7/10) of cases were JAK2 V617F mutated, 40% (4/10) had an additional IDH1/2 mutation and one case showed a coexisting ASXL1 mutation. As these mutations were identified in 10 cases, two cases had three alterations: DNMT3A, JAK2 and ASXL1 in one post-ET MF and DNMT3A, JAK2 and IDH2 in one sAML case. Despite the limited number of patients studied, the frequency of DNMT3A/IDH1/2 double-mutated sAML cases (80%, 4/5) is notable. This finding is in line with the data reported by Ley et al. 8 revealing a positive correlation between IDH1/2 and DNMT3A alterations in AML. In contrast, PV cases were characterized by the lowest frequency of DNMT3A alterations and lacked concurrent mutations beside JAK2 V617F. On the basis of these findings, mutations of DNMT3A appear to be n Indicates nonsense, fs indicates frameshift mutation.
Letters to the Editor preferentially associated with MF and sAML and may, therefore, represent an important event in clonal evolution of MPN. However, owing to lack of DNA from the preceding MPN phase, we were not able to perform sequential DNMT3A mutation analyses in cases with fibrotic or leukemic transformation.
In SNP array analysis, none of the patients showed genomic loss of DNMT3A mapping to 2p23.3. Furthermore, DNMT3A-altered PV cases lacked genomic aberrations, whereas the frequency was 50% (4/8) in MF and sAML; these cases showed genomic abnormalities associated with JAK2 V617F (uniparental disomies 9p (n ¼ 1) and trisomy 9 (n ¼ 2)), as well as large aberrations such as deletion 5q (18 Mb), loss of chromosome 7, trisomy 8 and trisomy 15 (n ¼ 1 each). Owing to the heterogeneity of these findings, DNMT3A alterations were not associated with a distinct pattern of genomic aberrations in SNP array analysis.
In terms of clinical data, our study does not allow to draw conclusions because of the limited number of DNMT3A mutations distributed among different MPN entities. The majority of cases (70%, 7/10) with DNMT3A alterations were associated with advanced disease phases such as secondary myelofibrosis (n ¼ 2) or leukemic transformation (n ¼ 5); none of the PV cases showed features of an aggressive clinical course, whereas outcome of sAML was poor: only 1/4 cases who received intensive chemotherapy is still alive; two cases underwent allogeneic stem cell transplantation and died thereafter because of infectious complications. However, longer observation time and systematic collection of clinical data will be necessary to clarify whether mutated DNMT3A is of clinical relevance in chronic-and blast-phase MPN.
In conclusion, this is the first report describing frequencies and molecular features of DNMT3A alterations in MPN. Our data underscore the increasing complexity of MPN pathogenesis due to the growing number of genetic lesions being identified. On the basis of our data, one might speculate that DNMT3A mutations represent an important mechanism for advanced phase disease in a subset of MPN cases. Genotyping of single colonies and functional studies will be necessary to further elucidate the pathogenic interplay between DNMT3A and other mutations such as JAK2, IDH1/2 and ASXL1 in terms of fibrotic and leukemic transformation. 
Table 2
Mutation patterns of cooperativity
Abbreviations: MF, myelofibrosis; PV, polycythemia vera; sAML, secondary acute myeloid leukemia. Recent reports have identified somatic mutations in DNMT3A in 4-22% of patients with de novo acute myeloid leukemia.
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These mutations, thought to result in a loss-of-function, were found to be predominantly heterozygous mutations in the methyltransferase domain, with a recurrent mutation at the R882 codon. In addition to DNMT3A mutations in acute myeloid leukemia, Walter et al. 3 have found DNMT3A mutations in 8% (12/150) of myelodysplastic syndromes patients as well. 3 Importantly, both Ley et al. and Walter et al. found that mutations in DNMT3A were associated with a worsened overall survival in both de novo acute myeloid leukemia and myelodysplastic syndromes, respectively.
Given these finding, we sequenced DNMT3A in a clinically and genetically well-annotated cohort of patients with primary myelofibrosis (PMF), the myeloproliferative neoplasm (MPN)/ myelodysplastic syndromes overlap syndrome chronic myelomonocytic leukemia (CMML) and advanced phases of MPNs in order to determine the genetic and clinical implications of DNMT3A mutations in this class of myeloid maligancies.
Study samples from 94 patients were recruited from the Mayo Clinic (n ¼ 94; 46 PMF, 22 post-polycythemia vera/essential thrombocythemia MF, 11 blast-phase MPN and 15 CMML). High throughput DNA resequencing was used to seqeunce bone marrow-derived DNA for all coding regions of DNMT3A (NM_175629). In addition, these samples were all previously sequenced for all coding regions of EZH2 (NM_015338), ASXL1 (NM_004456), and TET2 (NM_017628) and the regions of known mutations in IDH1, IDH2, JAK2 and MPL as previously reported. 4 CMML samples were also screened for known FLT3, K Ras and N Ras mutations. Non-synonymous alterations not in dbSNP were censored from analysis.
We identified three somatic mutations in DNMT3A in this cohort of patients (Table 1 ). All three mutations were heterozygous and occurred in patients with PMF resulting in a DNMT3A mutational frequency of 7% (3/46) in PMF. In addition to the R882H methyltransferase domain mutation found in one PMF patient, the other patients had heterozygous nucleotide deletions outside of the known domains of DNMT3A resulting in the occurrence of premature stop codons. All three PMF patients found to have a mutation in DNMT3A were also found to have a co-occuring mutation in another gene known to be mutated in MPNs, including co-occurences with mutations in JAK2, TET2 Letters to the Editor
